Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children

Low-dose interleukin-2 (IL-2) therapy for chronic graft-versus-host disease (cGVHD) generates a rapid rise in plasma IL-2 levels and CD4(+)CD25(+)CD127(−)Foxp3(+) regulatory T-cell (CD4Treg) proliferation, but both decrease over time despite continued daily administration. To test whether IL-2 dose...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Whangbo, Jennifer S., Kim, Haesook T., Mirkovic, Nikola, Leonard, Lauren, Poryanda, Samuel, Silverstein, Sophie, Kim, Soomin, Reynolds, Carol G., Rai, Sharmila C., Verrill, Kelly, Lee, Michelle A., Margossian, Steven, Duncan, Christine, Lehmann, Leslie, Huang, Jennifer, Nikiforow, Sarah, Alyea, Edwin P., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Blazar, Bruce R., Antin, Joseph H., Soiffer, Robert J., Ritz, Jerome, Koreth, John
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Transplantation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6737411/
https://ncbi.nlm.nih.gov/pubmed/31471324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000631
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars